Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended		242 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Consolidated Statements of Comprehensive Loss [Abstract]
Revenues	$ 530,720		$ 1,430,720
Operating expenses:
General and administrative	1,665,605	2,032,946	70,413,744
Research and development	50,750	93,319	116,092,348
Sublicense and option fees	26,536		26,536
Purchased in-process research and development			12,146,544
Operating expenses before accrual reversal	1,742,891	2,126,265	198,745,921
Accrual reversal		(561,195)	(561,195)
Total operating expenses	1,742,891	1,565,070	198,184,726
Loss from operations	(1,212,171)	(1,565,070)	(196,754,006)
Interest expense	(434,551)	(1,838,484)	(14,923,661)
Investment income	341	689	7,705,345
Other income (expense), net	905	43,814	(1,473,159)
Gain on early extinguishment of debt			6,277,100
Forgiveness of debt		476,837	476,837
Net loss	(1,645,476)	(2,882,214)	(198,691,544)
Preferred stock beneficial conversion feature			(8,062,712)
Accrual of preferred stock dividends and modification of warrants held by preferred stock stockholders			(1,229,589)
Net loss attributable to common stockholders	(1,645,476)	(2,882,214)	(207,983,845)
Other comprehensive income Net change in unrealized loss on marketable securities	(277,837)	(31,367)	309,204
Comprehensive loss	$ (1,923,313)	$ (2,913,581)	$ 208,293,049
Basic and diluted net loss attributable to common stockholders per share	$ (0.06)	$ (0.10)
Weighted average common shares outstanding	30,635,720	29,626,072